{"id":"NCT02427607","sponsor":"Eisai Co., Ltd.","briefTitle":"An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects","officialTitle":"An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-12","primaryCompletion":"2016-09-21","completion":"2016-11-09","firstPosted":"2015-04-28","resultsPosted":"2018-07-02","lastUpdate":"2018-07-02"},"enrollment":7,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Perampanel","otherNames":["Fycompa","E2007"]}],"arms":[{"label":"Perampanel","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Perampanel","timeFrame":"From first dose of study drug until perampanel was commercially available, up to approximately 1 year 5 months","effectByArm":[{"arm":"Perampanel","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Nasopharyngitis","Influenza","Fall","Head injury","Humerus fracture"]}}